Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
248 Leser
Artikel bewerten:
(1)

PCM TRIALS Expands Global Footprint with European Office

New London office allows leader in decentralized clinical trials to better serve Europe at a time when the global pandemic is creating greater demand for in-home services

DENVER, June 22, 2021 /PRNewswire/ -- PCM TRIALS, a leader in utilizing Certified Mobile Research Nurses (CMRNs) for decentralized clinical trials, announced today the opening of its London office to better serve biopharma companies and Contract Research Organizations (CROs) conducting trials throughout Europe. Although the company has completed many clinical trials in Europe since 2008, the new office will further enhance its ability to support work in that region of the world and respond to changing industry preferences for in-home trials as a result of the COVID pandemic.

Logo for PCM Trials, an independent provider of mobile research headquartered in Denver, Colorado, with European operations based out of the UK.

"Europe represents an important center of clinical research, which is why we opened an office in the United Kingdom. This office allows us to be more responsive to the needs of our research partners throughout Europe," said Greg Austin, president of Professional Case Management, the parent company of PCM Trials and a 30+ year industry leader in delivering specialized, in-home medical care.

According to Austin, the opening of the new office in London is only the first of many steps being taken to support the increasingly global nature of clinical trials.

For more than a decade, PCM Trials has effectively served in excess of 130 sponsors and dozens of CROs from its U.S. headquarters located in Denver, CO. The company has conducted decentralized clinical trials research on four continents for more than 270 protocols in more than 30 unique therapeutic areas.

While the company has served an increasing number of customers over the years, it saw its greatest growth in demand last year as it supported the clinical research community throughout the COVID pandemic. During the pandemic, PCM Trials completed 99.9% of its visits in-window.

"COVID created significant challenges for the clinical trial community, forcing a number of the trials to either be postponed or cancelled," said Austin. "Participants in these clinical trials were unable to access trial sites due to COVID-related restrictions. This impeded access meant that trials were at risk of not complying with the protocols which could have nullified the trial data. Since our CMRNs visit participants in their homes or places of employment, we are able to help our clinical research partners maintain the validity of their data set."

Austin noted that PCM Trials' direct-to-patient clinical research visits also enable more diversity in clinical trials, even when the world is not in the middle of a pandemic. "Because we can effectively reach a more diverse participant population, including rural and minority patients, we help our research partners provide meaningful results that are applicable to a broader array of patients," he said.

"While many other clinical trial providers solely contract with third-party nurse staffing agencies, we've built our reputation by hiring and certifying our own nurses on the unique needs of clinical trials and their participants. This direct relationship results in enhanced patient safety, faster trial completions, greater retention and data compliance," said Austin.

For more information about PCM Trials or to initiate an RFP for an upcoming trial, email info@pcmtrials.com.

About PCM Trials: PCM Trials is leading the global shift toward decentralized clinical trials by bringing clinical research to patients, wherever and whenever it is most convenient for them. PCM Trials directly recruits, trains, certifies, and manages Certified Mobile Research Nurses (CMRNs) to ensure that each visit meets the highest standards for data quality and patient experience. By reducing the barriers to participation, PCM Trials' mobile nurses support study recruitment, retention, adherence, and diversity. PCM Trials is an independent company headquartered in Denver, Colorado, with European operations based out of the UK, and has conducted more than 29,000 mobile research visits since 2008.

A PCM Trials Certified Mobile Research Nurse (CMRN) visits a patient in his home as part of a decentralized trial to save the patient the inconvenience of having to travel to a clinical site.

Logo - https://mma.prnewswire.com/media/1536525/PCM_Trials_Logo.jpg
Photo - https://mma.prnewswire.com/media/1536526/PCM_Trials_Certified_Mobile_Research_Nurse.jpg

© 2021 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.